GranuFlo Manufacturer Stands By its Product

Fresenius Medical Care North America, manufacturer of the controversial GranuFlo and NaturaLyte dialysis treatments, is standing by its products amid ongoing lawsuits. The pharmaceutical giant announced in December that it will fight on, and more suits are expected. The California GranuFlo lawyers at Nadrich & Cohen LLP are currently working with victims who have experienced severe side effects from GranuFlo.

GranuFlo is used for dialysis treatments in clinics across the nation. While they appear most often in Fresenius clinics, other facilities use them as well. The Food and Drug Administration approved GranuFlo for dialysis treatments, but amid serious side effects claims, the FDA quickly changed its tune.

The administration announced back in March of last year that it was issuing a Class I recall of the Naturalyte and GranuFlo Dry Acid Concentrate, a mixture used “in the treatment of acute and chronic renal failure during hemodialysis.” The Class I recall is the most serious type of FDA recall, used only in instances with a likelihood of serious adverse health effects or death.

According to the FDA’s recall announcement, Fresenius was “cautioning clinicians” that “[i]nappropriate prescription of these products can lead to a high serum bicarbonate level in patients undergoing hemodialysis,” which may trigger risk factors culminating in “cardiopulmonary arrest.”

So what exactly are these serious side effects? The most common fatal complication is heart attack. In fact, numerous suits have already been filed by the families of heart attack victims. One case, filed on December 11, 2012, alleges that a South Carolina man died after suffering a fatal heart attack following a GranuFlo procedure. Similar cases are also pending, and more are expecting.

The problem is that GranuFlo and NaturaLyte can cause dangerously high levels of bicarbonate in the bloodstream, which can lead to fatal side effects. The lawsuits allege that Fresenius knew of the risks and tried to conceal them from patients and the public.

If you or someone you love has experienced heart attack or death after receiving NaturaLyte or GranuFlo dialysis treatments, you may be entitled to compensation. You must act quickly, though, as litigation is already underway. The California GranuFlo lawyers at Nadrich & Cohen have recovered more than $1 billion for personal injury clients, and are currently accepting GranuFlo patients and their families as clients.

Give us a call at 1-800-718-4658 to receive a free, confidential consultation. We are contingency lawyers, and we won’t charge you any money if we don’t win your case. Don’t fight the battle alone. Call us today.

Do I Have A Case?

We offer free consultation. No office visit required, we will get back to you within 24 hours.

  • This field is for validation purposes and should be left unchanged.


What can we do for you?

  • Answer your legal question.
  • Provide a Free Case Evaluation.
  • Schedule an appointment.


Choose Us?

  • Available 24/7
  • Trusted Since 1990
  • Local to You
  • Recovered $350,000,000
  • 5 Star Reviews
  • Free Case Evaluation
  • VIP Service
  • No Win, No Fee

Latest Law Post

March 20, 2019

Valsartan Dangers: 3 Things You Should Know

Several drugs containing Valsartan have been  recalled in the U.S. because they contain impurities which may be cancer risks. You may be eligible for financial compensation if you took a drug containing Valsartan and have been diagnosed with cancer.

March 15, 2019

Expert Testifies Before House Subcommittee Regarding Talc Use And Ovarian Cancer Link

A United States House of Representatives subcommittee, on March 12th, 2019, looked into whether they should give the Food and Drug Administration (FDA) the power to more strictly regulate cosmetics, including talcum powder and products containing talc.


We are Personal Injury Lawyers representing accident victims throughout California.
For 30 years, the law firm of Nadrich & Cohen, LLP has helped injury victims
obtain the compensation they deserve.